Singaporean biotech, DotBio, is aiming to revolutionize cancer treatment by targeting exhausted T-cells with its tri-specific antibody, DB007. The antibody, built using DotBio’s modular DotBody technology, is designed to treat a broad range of solid tumors either as a standalone therapy or in combination with others.

In partnership with Bora Biologics, the companies aim to reach IND registration for DB007 to revolutionize cancer treatment. Bora’s expertise in early-phase biologics development, combined with their high-yield manufacturing at their Zhubei, Taiwan GMP facility and U.S. commercial facility will help to ensure global reach if successful.

Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company specializing in next-generation antibody therapies, in the development and manufacturing of DotBio’s lead asset, a novel tri-specific antibody, code name DB007, against undisclosed cancer targets.

Bora will support the development of DotBio’s lead asset, including its chemistry, manufacturing and controls (CMC) strategy, through to clinical development from its 48,400-square-foot (4,500-square-meter) centre-of-excellence in Zhubei, Taiwan.

“Bora Biologics offers a tailored development and manufacturing plan that provides end-to-end support for our client’s development programs,” commented Bobby Sheng, Chairman and CEO of Bora Group. “With operations up and running in Zhubei, Bora’s team of experts are ready to deliver high-yield processes together with the sophisticated program management capabilities necessary to successfully develop even the most challenging molecules.”

Ignacio Asial, Ph.D., Founder and CEO of DotBio said, “We chose Bora Biologics as our development partner because of its expertise in early-phase biologics development and solid track record in high-yield manufacturing of multi-specific antibody molecules. Bora’s early-clinical manufacturing facilities in Taiwan align perfectly with our current IND-development stage, while their large-scale, commercial-stage manufacturing and fill-and-finish facilities in the United States will support our goal to treat patients globally. I am thrilled to be working hand-in-hand with one of the best CDMO partners in Asia.”

Bora Biologics’ facility in Zhubei provides early-stage discovery research support, lead candidate screening, in vitro assays, and biochemical/physical assays, as well as preparation and purification of the most complex proteins, and monoclonal, bispecific and multi-specific antibodies and other recombinant proteins for research purposes.

For more, please find the original story source here.